Concepedia
Statistics
Publications
7
Citations
329
H-Index
Active since
1996
Affiliations
Cubist Pharmaceuticals (United States)(Current)
UCB Pharma (United Kingdom)
University of British Columbia
C4X Discovery (United Kingdom)
Pfizer (United States)
DAVID A. KAU is an author at Cubist Pharmaceuticals (United States) specializing in life sciences, microbiology, and biochemistry.
Publications per year
1996–2006
Genetic Engineering in Streptomyces roseosporus to Produce Hybrid Lipopeptide Antibiotics
Vivian Miao, Marie-François Coëffet-Le Gal, Kien T. Nguyen et al. · Chemistry & Biology · 2006 · 108 citations
Life Sciences, Biotechnology, Microbiology +16
A glutamic acid 3‐methyltransferase encoded by an accessory gene locus important for daptomycin biosynthesis in <i>Streptomyces roseosporus</i>
Kien T. Nguyen, DAVID A. KAU, Jian‐Qiao Gu et al. · Molecular Microbiology · 2006 · 68 citations
Life Sciences, Biochemistry, Microbiology +16
Identifying Protein Kinase Inhibitors Using an Assay Based on Inhibition of Aerial Hyphae Formation in Streptomyces.
Barbara Waters, Geeta Saxena, Yangsheng Wanggui et al. · The Journal of Antibiotics · 2002 · 55 citations · Full text
Life Sciences, Biochemistry, Microbiology +12
Novel Streptopyrroles from Streptomyces rimosus with Bacterial Protein Histidine Kinase Inhibitory and Antimicrobial Activities.
Sally J. Trew, Stephen K. Wrigley, L. PAIRET et al. · The Journal of Antibiotics · 2000 · 38 citations · Full text
Life Sciences, Microbiology, Molecular Biology +10
Novel β-Methoxyacrylates of the 9-Methoxystrobilurin and Oudemansin Classes Produced by the Basidiomycete <i>Favolaschia pustulosa</i>
Keith A. Wood, DAVID A. KAU, Stephen K. Wrigley et al. · Journal of Natural Products · 1996 · 29 citations
Pharmacy, Biochemistry, Chemistry +6
1–5 of 7